News: $RTIX RTI Surgical Inc (RTIX) Q1 2020 Earnings Call Transcript

Image source: The Motley Fool. RTI Surgical Inc   (NASDAQ: RTIX) Q1 2020 Earnings Call Jun 30, 2020 , 9:00 a.m. ET Operator Continue reading

Got this from RTIX - RTI Surgical Inc (RTIX) Q1 2020 Earnings Call Transcript

News: $RTIX Lawsuit for Investors in RTI Surgical Holdings, Inc. (NASDAQ: RTIX) shares announced by Shareholders Foundation

SAN DIEGO, June 30, 2020 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NASDAQ: RTIX shares. Investors, who purchased shares of RTI Surgical Holdings, Inc. (NASDAQ: RTIX), have certain options and should contact the Share...

Find out more RTIX - Lawsuit for Investors in RTI Surgical Holdings, Inc. (NASDAQ: RTIX) shares announced by Shareholders Foundation

News: $RTIX RTI Surgical Holdings, Inc.® Provides Business Updates

DEERFIELD, Ill., June 30, 2020 (GLOBE NEWSWIRE) -- RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today provided a business update in conjunction with releasing financial and operating results for the quarter ended March 31, 2020. Business Update Highligh...

Got this from RTIX - RTI Surgical Holdings, Inc.® Provides Business Updates

* * $RTIX Video Chart 04-28-2020 * *

Link to Video - click here to watch the technical chart video

HOD $3.40 so far...

$3.07 nice

* * $RTIX Video Chart 01-14-2020 * *

Link to Video - click here to watch the technical chart video

$RTIX I like this one

Nice news >

YUP! Real nice premarket!

Nice gap up this morning!

RTI Surgical Holdings, Inc.® Announces Sale of OEM Business and Preliminary Fourth Quarter and Full Year 2019 Revenues
Tweet Print
Alert
RTI Surgical (NASDAQ:RTIX)
Intraday Stock Chart
Today : Tuesday 14 January 2020

Click Here for more RTI Surgical Charts.
RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today announces a definitive agreement for the sale of the Company’s OEM business to Montagu Private Equity LLP (‘Montagu’), a leading European private equity firm, for a total consideration of $490 million. The transaction is targeted to close in the first half of 2020.
Transaction Overview

RTI Surgical Holdings has agreed to sell its OEM business to Montagu, a leading European private equity firm, for $480 million in cash and certain other consideration, totaling $490 million

The RTI Surgical Holdings Board of Directors unanimously approved the transaction

The transaction is subject to approval from RTI Surgical Holdings’ shareholders, the customary regulatory approvals and the satisfaction of customary closing conditions, and is targeted to close in the first half of 2020

Upon closure of the transaction, RTI Surgical Holdings will be a global pure play spine business focused on growth and innovation

After closing, the OEM business will continue under a contractual relationship to support RTI in developing and manufacturing certain products in RTI’s product portfolio

Proceeds from the transaction are currently expected to be used to repay indebtedness and to capitalize RTI Surgical Holdings for continued investment in its global spine portfolio
“The sale of the OEM business to Montagu completes the first phase of our strategic transformation to reduce complexity, drive operational excellence and accelerate the growth of RTI Surgical,” said Camille Farhat, President and CEO, RTI Surgical Holdings. “We are excited about this transaction, not only because of the value that is immediately created, but also because the OEM business is going to an experienced investor who understands the business and the expertise of the people and will support its growth and development.”

Mr. Farhat continued, “Following the transaction, we believe RTI will be a global pure play spine company with tremendous fundamentals and exciting long-term growth prospects. We estimate the spine business will have generated global revenues in the range of $118 million to $119 million with gross margins of approximately 75% in 2019. Immediately, post-transaction, the continuing business is expected to be debt-free and have approximately $175 million to $200 million of cash on the balance sheet to support its growth, which will be further driven by our Novel Therapies and an expected minimum of 10 new product introductions during each of the next two years.”

Olivier Visa, President of the OEM business commented, “We are thrilled about the sale of the OEM business to Montagu. We have built a world-class design, development and manufacturing competency with demonstrated expertise across tissue, biologics and hardware with a tremendous team and a customer base of leading medical technology companies. We are vested in continuing to build customer intimacy in service of our existing and future partners and continuing our legacy of serving more patients and maximizing the gift of donation. We look forward to working with Montagu in driving the growth of the business and deepening the significant expertise and core competencies we have developed to serve more patients.”

Guillaume Jabalot, Director, Montagu, said: “As a strong, resilient business that is well-positioned to capitalize on accelerated growth opportunities, RTI’s OEM business is an excellent fit for Montagu’s investment strategy. We look forward to working with Olivier and the team to support the business in this exciting next chapter of growth, maintaining its ethos of exceptional service and innovation.”

Preliminary Fourth Quarter and Full Year 2019 Results

For the fourth quarter of 2019, the Company expects to report revenues of $79 million to $80 million. In the quarter, OEM segment revenues are expected to be approximately $47 million and global Spine segment revenues are expected in the range of $32 million to $33 million primarily driven by solid progression of the Novel Therapies portfolio, delivering over 20% sequential growth compared to the third quarter 2019.

For the full year of 2019, the Company expects to report revenues of $307 million to $308 million. In the full year 2019, OEM segment revenues are expected to be approximately $189 million and global Spine segment revenues are expected in the range of $118 million to $119 million.

The Company will provide formal 2020 guidance for the global Spine business at the time of the transaction closing.

Piper Sandler acted as the exclusive financial advisor and rendered a fairness opinion to RTI Surgical Holdings, and Sidley Austin and Holland & Knight were RTI Surgical Holdings’ legal advisors on the transaction. Weil, Gotshal & Manges LLP acted as legal advisors to Montagu.

Conference Call
RTI will host a conference call and audio webcast at 8:30 a.m. ET on January 14, 2020. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International), using conference ID 3870628. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com/investors. A replay of the conference call will be available on RTI’s website for one month following the call.

About RTI Surgical Holdings, Inc.
RTI Surgical Holdings is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, plastic surgery, spine, orthopedic and trauma procedures and are distributed in over 50 countries. RTI has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com. Connect with us on LinkedIn and Twitter.

About Montagu
Montagu Private Equity is one of Europe’s leading private equity firms and has been investing in businesses for over fifty years. Montagu’s investment strategy is focused on partnership with management in buyouts of high-quality companies operating in stable and growing sectors, providing products and services that their customers would otherwise badly miss. It develops a shared strategic vision with management and then provides the necessary financial, strategic and operational resources to help realize that vision and support growth. The firm currently has assets under management of approximately €4.3 billion. Montagu partners with companies with enterprise values between €200 million and €1 billion and has made over 400 investments over the last fifty years. For additional information on Montagu, please visit www.montagu.com.

Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which may include statements regarding the impact of operational priorities on costs and their impact on RTI Surgical Holdings’ financial performance, RTI Surgical Holdings’ ability to meet its financial and other commitments, the implementation of RTI Surgical Holdings’ strategic initiatives, RTI Surgical Holdings’ ability to expand the number of patients it is able to serve, the impact of the transition from map3® to ViBone®, our growth strategy in spine, the expected integration of, and potential financial impact from various acquisitions, the success of our new product development and commercialization efforts, anticipated financial results, growth rates, future operational improvements, fiscal 2019 guidance and underlying assumptions, shareholder and regulatory approvals and the completion of the transaction. In particular, comments about RTI Surgical Holdings’ fundamentals and long-term growth prospects of RTI Surgical Holdings’ Spine business are forward-looking statements, as are expectations concerning fourth quarter 2019 revenues and the expected performance of Novel Therapies. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements are not guarantees of future performance and are based on certain assumptions including RTI Surgical Holdings’ ability to effectively manage expenses and accomplish its goals and strategies, the quality of the new product offerings from RTI Surgical Holdings, general economic conditions, as well as those within RTI Surgical Holdings’ industry, RTI Surgical Holdings’ ability to integrate acquisitions into existing operations, and numerous other factors and risks identified in the Company’s Form 10-K for the fiscal year ended December 31, 2018 and other filings with the Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Important factors that could cause actual results to differ materially from the anticipated results reflected in these forward-looking statements include risks and uncertainties relating to the following: (i) the risk that RTI Surgical Holdings may be unable to obtain shareholder approval for the proposed transaction or that RTI Surgical Holdings or Montagu may be unable to obtain regulatory approvals required for the proposed transaction, or required regulatory approvals may delay the proposed transaction; (ii) the risk that a condition to the closing of the proposed transaction may not be satisfied; (iii) the risk that the occurrence of an event that could give rise to termination of the definitive agreement; (iv) the risk that shareholder litigation in connection with the proposed transaction may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification and liability; (v) the timing to consummate the proposed transaction; (vi) the effect of the announcement or disruption from the proposed transaction making it more difficult to retain and hire key personnel and maintain relationships with customers, suppliers and other third parties; (vii) the diversion of management time and attention on the proposed transaction; (viii) general worldwide economic conditions and related uncertainties; (ix) the effect and timing of changes in laws or in governmental regulations; and (x) other risks described in our public filings with the SEC. Additional risks and uncertainties will be discussed in the proxy statement and other materials that RTI Surgical Holdings will file with the SEC in connection with the proposed transaction. There can be no assurance that the proposed transaction will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the proposed transaction will be realized. These factors should be considered carefully and undue reliance should not be placed on the forward-looking statements. Each forward-looking statement in this communication speaks only as of the date of the particular statement. Copies of the Company's SEC filings may be obtained by contacting the Company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov. We undertake no obligation to update these forward-looking statements except as may be required by law.

Important Additional Information and Where to Find It
The proposed transaction will be submitted to the shareholders of RTI Surgical Holdings for their consideration. In connection with the proposed transaction, RTI Surgical Holdings will file a proxy statement and other materials with the SEC. This communication is not a substitute for the proxy statement or any other document that RTI Surgical Holdings may send to its shareholders in connection with the proposed transaction.

RTI SURGICAL HOLDINGS SHAREHOLDERS ARE ADVISED TO READ THE PROXY STATEMENT FOR THE PROPOSED TRANSACTION WHEN IT IS FILED, AND ANY AMENDMENT OR SUPPLEMENT THERETO THAT MAY BE FILED, WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT RTI SURGICAL HOLDINGS AND THE PROPOSED TRANSACTION. All such documents, when filed, are available free of charge at the SEC’s website, www.sec.gov, from the Company at its website, www.rtix.com, or by contacting the Company’s Investor Relations at (847) 530-0249.

Participants in Solicitation
RTI Surgical Holdings and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information concerning RTI Surgical Holdings’ participants is set forth in the proxy statement, filed March 25, 2019, for the Company’s 2019 annual meeting of stockholders as filed with the SEC on Schedule 14A. Additional information regarding the interests of such participants in the solicitation of proxies in respect of the proposed transaction will be included in the proxy statement and other relevant materials to be filed with the SEC when they become available.

Media and Investor Contact
Molly Poarch
mpoarch@rtix.com
+1 224 287 2661

News: $RTIX RTI Surgical® Showcases Advancements in Spine Portfolio and Clinical Data at NASS 2019

CHICAGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, will showcase its expanding portfolio and body of clinical data to reinforce the growing strength of its spine business at the North American Spine Society’s (NA...

In case you are interested RTIX - RTI Surgical® Showcases Advancements in Spine Portfolio and Clinical Data at NASS 2019

RTI Surgical® Announces Commercial Launch of the CervAlign® Anterior Cervical Plate System
Date : 09/24/2019 @ 7:05AM
Source : GlobeNewswire Inc.
Stock : RTI Surgical Holdings Inc (RTIX)
Quote : 3.1 0.0 (0.00%) @ 4:00AM

RTI Surgical® Announces Commercial Launch of the CervAlign® Anterior Cervical Plate System
Print
Alert
RTI Surgical (NASDAQ:RTIX)
Intraday Stock Chart
Today : Tuesday 24 September 2019

Click Here for more RTI Surgical Charts.
RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today announced the full commercial launch of the CervAlign® Anterior Cervical Plate (ACP) System to add to the growth of its Established Therapies spine portfolio.
The CervAlign ACP System is designed to promote cervical fusion by providing temporary resistance to flexion, extension, lateral bending and axial rotation with strength and stiffness in the cervical spine (C2-C7). The system includes implants of various plate and screw sizes to accommodate varying patient anatomies. It also helps reduce complexity for the surgeon customer with an integrated cover-style locking mechanism that adds zero profile, streamlined instrumentation with the same driver for screws, pins, locking and revisions, and low-profile plates ranging from one to five levels, each with large graft windows for intraoperative visibility. Additionally, using the Fortilink®-C Interbody Fusion (IBF) System with TETRAfuse® 3D Technology and ViBone® Viable Bone Matrix with the CervAlign ACP provides surgeons a complete anterior cervical discectomy and fusion (ACDF) solution.

“The locking mechanism on the CervAlign ACP System is easily visible and engaged, and there is no guesswork as to whether it is completely locked,” said Franco E. Vigna, MD, MPH, FACOS of reVive Spine Center in Buffalo, New York. “Additionally, the amount of screw angulation allows for use of a shorter plate. Combined with the large graft windows and visibility of the plate, it allows surgeons to easily instrument the hard-to-access levels such as C3.”

The CervAlign ACP System is intended for anterior cervical fixation (C2-C7) for the following conditions: degenerative disc disease (DDD) defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies, spondylolisthesis, trauma (e.g., fracture or dislocation), spinal stenosis, deformities or curvatures (e.g., scoliosis, kyphosis, and/or lordosis), tumor, pseudarthrosis and failed previous fusion.

“After a successful Limited Market Release, we are excited to commercially launch the CervAlign ACP system to offer a plate with a cover-style locking mechanism and streamlined instrumentation,” said Camille Farhat, President and CEO. “This is a great example of how we plan to use home-grown innovation to accelerate our spine business. CervAlign ACP adds another option for surgeons in our current Established Therapies portfolio, which we have recently reinvigorated through our R&D efforts across hardware, interbodies and biologics. As we further accelerate growth in spine, we will be able to meet the demands of more surgeons and treat more patients.”

About RTI Surgical Holdings, Inc.

RTI Surgical?is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in spine, sports medicine, general surgery, orthopedic and trauma procedures and are distributed in nearly 50 countries. RTI has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, visit www.rtix.com. Connect with us on LinkedIn and Twitter.

Molly Poarch
Investor Contact
mpoarch@rtix.com
+1 224 287 2661

Steven Cohen
Media Contact
scohen@rtix.com
+1 847 648 0861

Really like RTIX upside before earnings tomorrow...


Fair Value

After hours up 20% Wow... This company is moving along nicely and has MultiStem behind it...

I bought a few shares for the Roth IRA in 2013 of this stock...was alerted as a subscriber to GorillaTrades of "special situation" potential as I think it was not a big enough company to be some kind of regular confirmed Gorilla pick. Looking to probably start adding a few more shares gradually as 2014 progresses. (Not much action on this board, eh?)

Was just poking around and saw this one on a scanner. Looks interesting technically.

8:03AM RTI Surgical announces successful outcome to FDA inspection of Alachua, Fla. Facility (RTIX) 3.51 : Co announced that on Sept. 9 and 10 the Food and Drug Administration (FDA) performed an inspection of the company's Alachua, Fla. facility to verify effective implementation of the corrective actions taken after the company received a warning letter in October 2012. Upon completion of the inspection, inspectors noted the adequacy and effectiveness of the voluntary corrective actions and acknowledged the significant improvement in RTI's overall environmental monitoring program. All items in the warning letter were closed, and no new items, issues or FDA 483 observations were issued as part of this inspection.

~ $RTIX ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!

$RTIX has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "RTIX" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "RTIX": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=RTIX ~
Search Ihub for "RTIX" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=RTIX ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~


c

There is a lot of upside in this company. I live near the headquarters and they are expanding quite a bit.

Furthermore, they should show some signs of recovery after getting that FDA letter off their back

7:02AM RTI Biologics announces agreement to acquire Pioneer Surgical Technology for $130 mln in cash (RTIX) 4.40 : Co announced its intent to acquire privately held Pioneer Surgical Technology, headquartered in Marquette, Mich. Under the terms of the merger agreement, RTI will pay $130 mln in cash to acquire all the outstanding stock of Pioneer.

The transaction will be funded through a combination of cash on hand, a new credit facility and a concurrent private placement of convertible preferred equity from Water Street Healthcare Partners. RTI has received a commitment from TD Bank, TD Securities "USA" and Regions Bank for a 5-year, $80 mln senior secured facility, which includes a $60 mln term loan and a $20 mln revolving credit facility.

Additionally, RTI has agreed to a $50 mln private placement of convertible preferred equity with Water Street. After the merger transaction is complete, Brian Hutchison, RTI president and chief executive officer, and Robert Jordheim, RTI executive vice president and CFO, will continue to serve in their respective roles. The combined company will be headquartered in Alachua, Fla. The merger agreement has been approved by both companies' boards of directors. The merger is subject to customary closing conditions and regulatory approvals. The transaction is expected to close in the third quarter of 2013.

Down to $4 with earnings report: See Surf's post. $4

8:06AM RTI Biologics reports EPS in-line, misses on revs; guides Q1 EPS below consensus, revs below consensus; guides FY13 EPS below consensus, revs below consensus (RTIX) 4.74 : Reports Q4 (Dec) earnings of $0.04 per share, in-line with the Capital IQ Consensus Estimate consensus of $0.04; revenues rose 4.0% year/year to $44.6 mln vs the $45.11 mln consensus.

Co issues downside guidance for Q1, sees EPS of ~$0.02 vs. $0.05 Capital IQ Consensus Estimate; sees Q1 revs of $38-39 mln vs. $46.04 mln Capital IQ Consensus Estimate. Co issues downside guidance for FY13, sees EPS of $0.17-0.19 vs. $0.22 Capital IQ Consensus Estimate; sees FY13 revs of $178-182 mln vs. $188.49 mln Capital IQ Consensus Estimate.

"Due to customer reaction to the FDA warning letter and inaccuracies in media coverage in 2012, we expect a weaker first half of the year. Following the anticipated closure of the warning letter, expansion of our direct distribution business and the launch of several new implants, we expect the second half of the year to be strong," said Hutchison. "We also expect that the investments we are making in new products and direct distribution, combined with our active business development efforts, will accelerate our future revenue growth.

Stem Cell Therapy Companies: Underappreciated Outperformers

http://seekingalpha.com/article/1139911-stem-cell-therapy-companies-underappreciated-outperformers?source=yahoo

http://www.rtix.com/investors/events-webcasts/

RTI Biologics, Inc. (RTIX)
Sector Healthcare
Industry Medical Appliances & Equipment
Market Cap $213.50M
Beta 1.49

RTIX stock chart

Key Metrics
Debt/Equity Ratio 0.01
Long Term Debt/Equity Ratio 0.01
1-Year Projected Earnings Per Share Growth Rate 46.67%
Short Interest 3.91%

RTI Biologics, Inc., together with its subsidiaries, produces orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The company processes donated human musculoskeletal and other tissues, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera, and dermal tissues, as well as bovine animal tissues to produce allograft and xenograft implants by utilizing its proprietary BIOCLEANSE and TUTOPLAST sterilization processes. It processes and distributes human and bovine animal tissues for use in the fields of sports medicine, spine, dental, surgical specialties, bone graft substitutes, and general orthopedic. RTI Biologics, Inc. markets its products through its direct distribution force, as well as through a network of independent distributors to hospitals and surgeons in the United States and 30 countries internationally. The company was formerly known as Regeneration Technologies, Inc. and changed its name to RTI Biologics, Inc. as a result of its merger with Tutogen Medical, Inc. in February 2008. RTI Biologics, Inc. was founded in 1997 and is headquartered in Alachua, Florida.

http://seekingalpha.com/article/824921-3-high-growth-low-debt-healthcare-microcaps?source=yahoo

29-Jun-12 Northland Securities Initiated Market Perform

RTI Biologics, Inc. (RTIX) process human musculoskeletal and other tissue. It also processes bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine animal tissue in producing allograft and xenograft implants utilizing biocleanse and tutoplast sterilization processes, for distribution to hospitals and surgeons. The current market price is $3.65 with a one-year analyst price target of $5.13. This represents a 40.55% upside potential.

Over the past three years, the company has reported three positive (>2%), zero negative, and one in-line (within 2%) surprises. The average surprise for this time period has been 26.0%. Most recently on 01/31/12, the company reported quarterly earnings of 0.04 per share, a positive surprise of 25.0% above the consensus 0.03. For fiscal year 2012, analysts estimate that RTIX will earn $0.16 and for 2013, analysts estimate that RTIX's earnings per share will grow by 37% to $0.22. Over the past five years EPS growth rate has been 35.21% and are expected to be 28.40% over the next five years. RTIX has a long-term debt / equity ratio of 0 and a PEG of 0.87 further making this a great value stock that is poised for growth.

http://seekingalpha.com/article/441311-4-extremely-undervalued-stocks-to-add-to-your-portfolio?source=yahoo

Into Thursday there..

~ $RTIX ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $RTIX ~ Earnings expected on Thursday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=RTIX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=RTIX&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/RTIX?
~ OTC Markets: http://www.otcmarkets.com/stock/RTIX/company-info
~ Google Finance: http://www.google.com/finance?q=RTIX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=RTIX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=RTIX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=RTIX
Finviz: http://finviz.com/quote.ashx?t=RTIX
~ BusyStock: http://busystock.com/i.php?s=RTIX&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=RTIX&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=RTIX
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=RTIX
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=RTIX
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=RTIX
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=RTIX
~ MarketWatch: http://www.marketwatch.com/investing/stock/RTIX/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=RTIX
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=RTIX
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=RTIX&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=RTIX&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=RTIX&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

~ $RTIX ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $RTIX ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=RTIX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=RTIX&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/RTIX?
~ OTC Markets: http://www.otcmarkets.com/stock/RTIX/company-info
~ Google Finance: http://www.google.com/finance?q=RTIX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=RTIX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=RTIX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=RTIX
Finviz: http://finviz.com/quote.ashx?t=RTIX
~ BusyStock: http://busystock.com/i.php?s=RTIX&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=RTIX&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=RTIX
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=RTIX
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=RTIX
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=RTIX
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=RTIX
~ MarketWatch: http://www.marketwatch.com/investing/stock/RTIX/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=RTIX
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=RTIX
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=RTIX&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=RTIX&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=RTIX&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

8:02AM RTI Biologics beats by $0.01, beats on revs; guides Q1 slightly below consensus; guides FY12 EPS slightly below consensus and revs in-line (RTIX) 3.99 : Reports Q4 (Dec) earnings of $0.04 per share, $0.01 better than the Capital IQ Consensus Estimate of $0.03; revenues fell 5.5% year/year to $42.9 mln vs the $41.22 mln consensus. Co sees Q1 EPS of ~$0.03 vs. $0.04 Capital IQ Consensus Estimate; sees Q1 revs of $41-42 mln vs. $42.64 mln Capital IQ Consensus Estimate. Co sees FY12 EPS of $0.15-0.17 vs. $0.19 Capital IQ Consensus Estimate; sees FY12 revs of $174-176 mln vs. $175.85 mln Capital IQ Consensus Estimate

RTI Biologics Launches AllograftInfo.com Educational Website

Informational Portal Educates Patients, Public About Allograft Tissue
Business WirePress Release: RTI Biologics Inc. – Tue, Jan 10, 2012 3:30 PM EST

ALACHUA, Fla.--(BUSINESS WIRE)-- RTI Biologics Inc. (RTI) (Nasdaq: RTIX - News), a leading provider of orthopedic and other biologic implants, has launched an informational website to educate patients and the general public about allograft tissue. AllograftInfo.com explores the use of allograft, or human donated tissue, in surgery, as well as provides links to relevant research and articles. The website also addresses several frequently asked questions and provides suggestions on what to ask your surgeon when considering allograft.

“AllograftInfo.com is a website we created based on surgeon feedback to provide patients a convenient and easy-to-understand portal for self-education on allograft tissue," said Brian K. Hutchison, president and chief executive officer. “RTI believes in the life-changing benefits of allograft implants, and we hope this website helps the public and potential patients better understand allograft tissue as an available option in a variety of surgeries.”

An allograft is tissue surgically transplanted from one person to another. Most allograft tissue is recovered surgically after death; the donor must have consented to the donation before death or the donor’s family must consent after death. Allografts have been used successfully for more than 150 years, and approximately one million allografts are transplanted each year in the United States in procedures that include ACL repair, joint reconstruction in the knee and ankle, meniscal replacement, reconstruction due to cancer or trauma, ridge augmentation in dental procedures, shoulder repair, spinal fusion and urological procedures.

Allografts are used as an alternative to synthetic and metal implants. However, unlike synthetic or metal implants, allografts are natural and biocompatible scaffolds, allowing the recipient’s body to remodel it into his or her own tissue over time. Using allograft tissue rather than an autograft – or tissue from one’s own body – eliminates a second surgical site, allowing the recipient to avoid additional pain, risk and a possible longer hospital stay.

RTI honors the gift of tissue donation by treating the tissue with respect, by finding new ways to use the tissue to help patients and by helping as many patients as possible from each donation.

About RTI Biologics

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of millions of implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

8:08AM RTI Biologics beats by $0.02, beats on revs; guides FY11 EPS in-line, raises FY rev guidance; above consensus (RTIX) 3.76 : Reports Q3 (Sep) earnings of $0.05 per share, $0.02 better than the Capital IQ Consensus Estimate of $0.03; revenues rose 1.2% year/year to $42.3 mln vs the $40.6 mln consensus. Co issues mixed guidance for FY11, sees EPS of $0.12-0.14 vs. $0.13 Capital IQ Consensus Estimate; sees FY11 revs of $166-167 mln vs. $165.99 mln Capital IQ Consensus Estimate and above prior guidance of $164-166 mln.

I cant believe more people are not talking about this stock. Its a company showing solid growth. I listened to their last CC and management sounds like they wanted to be even more upbeat but held back to keep it safe. Not to mention looking at the chart someone has been buying the crap out of it the last two months. I have looked at the buys vs sells the last month and its like 3-1 on the buy side atleast 3 days a week. I say this breaks $4 and heads toward 4.50-5.00 soon. If they come out with better earnings then their already upped guidance then you will see a buying frenzy IMO.

4 Healthcare Stocks With Positive Correlation To Market Volatility

3. RTI Biologics, Inc. (RTIX): Produces orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues, and improve surgical outcomes. Market cap of $190.30M. Correlation to the VIX index at 0.64. The stock has had a couple of great days, gaining 11.65% over the last week.

http://seekingalpha.com/article/294894-4-healthcare-stocks-with-positive-correlation-to-market-volatility?source=yahoo

RTI Biologics Has Great Growth Potential

While screening on Barchart for small cap stocks having great price momentum I came across RTI Biologics (RTIX), an undiscovered stock that is beginning to be put on analysts' watch lists. The bio-medical sector is starting to move and the product line of this stock is wanted and necessary. Just look at the 11 new highs and 14.24% price appreciation this stock received even in a soft market.

RTI Biologics, Inc. and its subsidiaries produce orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improves surgical outcomes. The company processes human musculoskeletal and other tissues, including bone, cartilage, tendon, ligament, fascia lata, pericardium and sclera and dermal tissues into allografts, as well as bovine animal tissues into xenografts for distribution to hospitals and surgeons. It processes and distributes human and bovine animal tissues for spine, sports medicine, dental, surgical specialties, bone graft substitutes and general orthopedic markets in the United States and internationally. The company was founded in 1997 and is headquartered in Alachua, Florida. (Yahoo Finance profile)

Barchart technical indicators:

96% Barchart technical buy signals.
Trend Spotter buy signal.
Above its 20, 50 and 100 day moving averages.
11 new highs and up 14.24% in the last month.
Relative Strength Index 60.27% and rising.
Barchart computes a support level at 3.24.
Traded recently at 3.43 which is above its 50 day moving average of 3.05.

Fundamental factors to consider:

Wall Street analysts are beginning to follow this stock but as yet haven't published any buy signals.
Earnings are projected to increase by 30.00% this year, another 30.80% next year and continue for the next 5 years at 26.95% annually.

General investor sentiment:

Readers on Motley Fool are starting to put this stock on their watch lists and the 229 readers who have expressed an opinion voted 95% that the stock will beat the market.
The more experienced All Stars are more positive with a 97% vote for the same result.

Summary: RTI Biologics is in that sweet spot I like for speculative growth stocks. It has press and is being followed by major stock information sites like Value Line and Motley Fool and has drawn the attention of Wall Street analyst but as yet has not been added to any of their model portfolios. I couldn't pass up these aggressive double digit earnings projects and have added it to both my own account and the accounts of my managed money portfolios.

I think the cultured bone and tissue industry will be a big medical growth area and this company has proven products. Because of its low price and high P/E ration this stock should be acquired only for speculative portfolios but deserves a place on the watch lists of all growth oriented investors.

Disclosure: I am long RTIX. I own the stock personally and it is a position in my clients' managed money portfolios.

when you posted break, I guess you meant break down

Churning just below 52 week high, with above average volume. Looks like it might break tonight

8:01AM RTI Biologics beats by $0.01, beats on revs; guides Q3 EPS in-line, revs above consensus; guides FY11 EPS above consensus, revs above consensus (RTIX) 2.98 : Reports Q2 (Jun) earnings of $0.04 per share, $0.01 better than the Capital IQ Consensus Estimate of $0.03; revenues rose 5.8% year/year to $43.5 mln vs the $40.5 mln consensus. Co issues mixed guidance for Q3, sees EPS of $0.03 vs. $0.03 Capital IQ Consensus Estimate; sees Q3 revs of $40-41 mln vs. $39.01 mln Capital IQ Consensus Estimate. Co issues upside guidance for FY11, sees EPS of $0.12-0.14 vs. $0.12 Capital IQ Consensus Estimate; sees FY11 revs of $164-166 mln vs. $161.82 mln Capital IQ Consensus Estimate.

4:00PM RTI Biologics announces launch of BioAdapt DBM foam (RTIX) 2.71 -0.04 : The first implantation occurred June 24, 2011 in a foot and ankle procedure